Muraglitazar, a Novel Dual (α/γ) Peroxisome Proliferator–Activated Receptor Activator, Improves Diabetes and Other Metabolic Abnormalities and Preserves β-Cell Function in db/db Mice
暂无分享,去创建一个
Michael Cap | R. Gregg | W. Fenderson | Wen-pin Yang | R. Seethala | T. Harrity | K. Mookhtiar | Pratik Devasthale | Fucheng Qu | Denis E. Ryono | Hao Zhang | Dennis Farrelly | Ramakrishna Seethala | Narayanan Hariharan | Scott A. Biller | John R. Wetterau | L. Kunselman | Richard E. Gregg | Thomas Harrity | Wei Wang | Wen-Pin Yang | J. Wetterau | Aaron Tieman | Cuixia Chu | Lori Kunselman | Liqun Gu | Randolph P. Ponticiello | Chunning Shao | William Fenderson | Chen Sean | T JeonYoon | Jimmy Ren | Min Zhou | Kasim A. Mookhtiar | Peter T. W. Cheng | N. Hariharan | S. Biller | D. Ryono | Hao Zhang | M. Cap | D. Farrelly | Jimmy Ren | F. Qu | P. Devasthale | P. Cheng | Liqun Gu | C. Chu | Chunning Shao | A. Tieman | R. Ponticiello | Min-bao Zhou | Wei Wang | P. T. Cheng | Chen. Sean | T. JeonYoon | Dennis Farrelly | Aaron Tieman
[1] Philippe Froguel,et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects , 2003, Nature.
[2] L. Madsen,et al. PPARa activators improve insulin sensitivity and reduce adiposity , 2000 .
[3] M. Rossmeisl,et al. Variation in type 2 diabetes--related traits in mouse strains susceptible to diet-induced obesity. , 2003, Diabetes.
[4] T. Larsen,et al. PPARgamma agonists in the treatment of type II diabetes: is increased fatness commensurate with long-term efficacy? , 2003, International Journal of Obesity.
[5] Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study , 2001, The Lancet.
[6] R. Heyman,et al. RXR agonists activate PPARalpha-inducible genes, lower triglycerides, and raise HDL levels in vivo. , 1998, Arteriosclerosis, thrombosis, and vascular biology.
[7] S. Horwitz,et al. Mechanism of action of taxol. , 1992, Trends in pharmacological sciences.
[8] P. Froguel,et al. Impaired Multimerization of Human Adiponectin Mutants Associated with Diabetes , 2003, Journal of Biological Chemistry.
[9] S. O’Rahilly,et al. Induction of Adipocyte Complement-Related Protein of 30 Kilodaltons by PPARγ Agonists: A Potential Mechanism of Insulin Sensitization. , 2002, Endocrinology.
[10] R. Infante,et al. Effects of ciprofibrate and fenofibrate on liver lipids and lipoprotein synthesis in normo- and hyperlipidemic rats. , 1988, Atherosclerosis.
[11] C. Cobelli,et al. Impaired basal glucose effectiveness but unaltered fasting glucose release and gluconeogenesis during short-term hypercortisolemia in healthy subjects. , 2004, American journal of physiology. Endocrinology and metabolism.
[12] B. Staels,et al. The role of PPARs in atherosclerosis. , 2002, Trends in molecular medicine.
[13] Toshiaki Tanaka,et al. Pioglitazone improves insulin secretory capacity and prevents the loss of beta-cell mass in obese diabetic db/db mice: Possible protection of beta cells from oxidative stress. , 2004, Metabolism: clinical and experimental.
[14] R. Bergman,et al. Free Fatty Acids and Pathogenesis of Type 2 Diabetes Mellitus , 2000, Trends in Endocrinology & Metabolism.
[15] F. Murray,et al. Pioglitazone preserves pancreatic islet structure and insulin secretory function in three murine models of type 2 diabetes. , 2004, American journal of physiology. Endocrinology and metabolism.
[16] Bruno Derudas,et al. Peroxisome Proliferator-activated Receptor α Activators Improve Insulin Sensitivity and Reduce Adiposity* , 2000, The Journal of Biological Chemistry.
[17] Peter Libby,et al. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. , 2002, JAMA.
[18] D. Hassall,et al. PPAR agonists as direct modulators of the vessel wall in cardiovascular disease , 2000, Medicinal research reviews.
[19] M. Connock,et al. A sensitive spectrophotometric assay for peroxisomal acyl-CoA oxidase. , 1985, The Biochemical journal.
[20] John A Wagner,et al. Complex Distribution, Not Absolute Amount of Adiponectin, Correlates with Thiazolidinedione-mediated Improvement in Insulin Sensitivity* , 2004, Journal of Biological Chemistry.
[21] H. Lebovitz,et al. Differentiating members of the thiazolidinedione class: a focus on safety , 2002, Diabetes/metabolism research and reviews.
[22] L. Abrahmsén,et al. Selective inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains. , 2003, Endocrinology.
[23] K. Ogilvie,et al. A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptor-alpha/gamma agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models. , 2002, Diabetes.
[24] Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. , 2001 .
[25] Cynthia J. Girman,et al. Plasma adiponectin levels and risk of myocardial infarction in men. , 2004, JAMA.
[26] J. Berger,et al. The mechanisms of action of PPARs. , 2002, Annual review of medicine.
[27] T. Kadowaki,et al. Adiponectin and adiponectin receptors. , 2005, Endocrine reviews.
[28] T. Willson,et al. Peroxisome proliferator-activated receptors: from genes to physiology. , 2001, Recent progress in hormone research.
[29] J Auwerx,et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. , 1998, Circulation.
[30] B. Ljung,et al. AZ 242, a novel PPARα/γ agonist with beneficial effects on insulin resistance and carbohydrate and lipid metabolism in ob/ob mice and obese Zucker rats Published, JLR Papers in Press, August 16, 2002. DOI 10.1194/jlr.M200127-JLR200 , 2002, Journal of Lipid Research.
[31] J. Olefsky. Treatment of insulin resistance with peroxisome proliferator–activated receptor γ agonists , 2000 .
[32] T. Saruta,et al. Combination therapy with PPARγ and PPARα agonists increases glucose-stimulated insulin secretion in db/dbmice , 2003 .
[33] L. J. Hardies,et al. Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients , 2004, International Journal of Obesity.
[34] Y. Yazaki,et al. A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-alpha (PPAR-alpha) and PPAR-gamma: effect of PPAR-alpha activation on abnormal lipid metabolism in liver of Zucker fatty rats. , 1998, Diabetes.
[35] S. Connor,et al. Antidiabetic Efficacy of BRL 49653, a Potent Orally Active Insulin Sensitizing Agent, Assessed in the C57BL/KsJ db/db Diabetic Mouse by Non‐invasive 1H NMR Studies of Urine , 1997, The Journal of pharmacy and pharmacology.
[36] T. Buchanan,et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. , 2002, Diabetes.
[37] T. Saruta,et al. Erratum: Combination therapy with PPARγ and PPARα agonists increases glucose-stimulated insulin secretion in db/db mice (American Journal of Physiology-Endocrinology and Metabolism (May 2003) 284 (E966-E971)) , 2003 .
[38] R. Saladin,et al. Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight. , 2000, Biochemical and biophysical research communications.
[39] Weiqi Wang,et al. Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor alpha/gamma dual agonist with efficacious glucose and lipid-lowering activities. , 2005, Journal of medicinal chemistry.
[40] R. DeFronzo,et al. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. , 2004, The Journal of clinical endocrinology and metabolism.
[41] R. Chakrabarti,et al. Ragaglitazar: a novel PPARα & PPARγ agonist with potent lipid‐lowering and insulin‐sensitizing efficacy in animal models , 2003 .
[42] P. Lind. Interdependence of hepatic lipid and glucose metabolism: novel pharmacological targets for diabetes. , 2004, Current opinion in investigational drugs.
[43] Sander Kersten,et al. Roles of PPARs in health and disease , 2000, Nature.
[44] K. Wassermann,et al. The dual PPARα/γ agonist, ragaglitazar, improves insulin sensitivity and metabolic profile equally with pioglitazone in diabetic and dietary obese ZDF rats , 2005 .